Medicine and Dentistry
Kidney Metastasis
100%
Clear Cell Renal Cell Carcinoma
65%
Overall Survival
62%
Hazard Ratio
29%
Immunotherapy
29%
Targeted Therapy
27%
Nephrectomy
25%
Kidney Cancer
20%
Combination Therapy
15%
Progression Free Survival
14%
Neoplasm
13%
Adverse Event
13%
Prognostic Factor
12%
T Cell
12%
Recurrent Ovarian Cancer
12%
Vasculotropin
12%
Natural Killer Cell
12%
Interleukin 2
12%
Lymphocyte
12%
Nivolumab
12%
Ipilimumab
12%
Oncology
11%
Immunoglobulin
10%
Recurrent Disease
10%
Clear Cell
9%
Sunitinib
9%
Neutrophil
9%
Biological Marker
9%
Clinical Trial
8%
Krukenberg Tumor
7%
Breast Cancer
7%
Comorbidity
7%
Monotherapy
6%
Hyponatremia
6%
Malignant Neoplasm
6%
Immunocompetent Cell
6%
Metastasectomy
6%
Adjuvant Therapy
6%
Programmed Death-Ligand 1
6%
Survival Rate
6%
Placebo
6%
Von Hippel-Lindau Disease
6%
Observational Study
6%
Everolimus
6%
Cancer Registry
6%
Immune Checkpoint Inhibitor
6%
Cohort Analysis
6%
Kidney Carcinoma
6%
Urology
6%
Brain Metastasis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
90%
Renal Cell Carcinoma
57%
Overall Survival
49%
Kidney Cancer
19%
Biological Marker
19%
Interleukin 2
18%
Progression Free Survival
17%
Immunotherapy
16%
Neoplasm
15%
Pazopanib
13%
Adverse Event
13%
Ipilimumab
12%
Nivolumab
12%
Combination Therapy
11%
Immunoglobulin
10%
Sunitinib
9%
Hyponatremia
6%
Monotherapy
6%
Interferon
6%
Bevacizumab
6%
Vasculotropin
6%
Bilirubin
6%
Pembrolizumab
6%
Kidney Carcinoma
6%
Everolimus
6%
Iodinated Contrast Medium
6%
Glucuronosyltransferase 1A1
6%
Phase II Trials
6%
Brain Metastasis
6%
Hepatotoxicity
6%
Lymphocytopenia
6%
Hyperbilirubinemia
6%
Sodium Fluoride
6%
Immunology and Microbiology
Carcinoma Cell
63%
Overall Survival
27%
Interleukin 2
18%
Natural Killer Cell
12%
Neutrophil
9%
Immunocompetent Cell
7%
interferon
6%
Bevacizumab
6%
Mortality Rate
6%
FOXP3
6%
Prognostic Biomarker
6%
Tincture of Iodine
6%
T Cell
6%
Iodinated Contrast
6%
Contrast Medium
6%
CD163
6%
Comorbidity
6%
